Skip to main content

Table 3 Treatment characteristics by period

From: The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation

Characteristics

All

1993–2003

2003–2010

n

%

n

%

n

%

Chemotherapy

 None

236

56.3%

95

58.3%

141

55.1%

 Oral pyrimidine fluoride agents

77

18.4%

60

36.8%

17

6.6%

 Anthracycline-based regimen

26

6.2%

3

1.8%

23

9.0%

 Anthracycline plus taxane regimen

54

12.9%

3

1.8%

51

19.9%

 Taxane-based regimen

37

8.8%

0

0.0%

37

14.5%

 Trastuzumab

23

5.5%

2

1.2%

21

8.2%

 Others

4

1.0%

1

0.6%

3

1.2%

Endocrine therapy

 None

117

27.9%

61

37.4%

56

21.9%

 SERM or AI

232

55.4%

88

54.0%

144

56.3%

 SERM + LHRHa

61

14.6%

13

8.0%

48

18.8%

 Others

9

2.1%

1

0.6%

8

3.1%

  1. Abbreviations: SERM Selective estrogen receptor modulator, AI Aromatase inhibitor, LHRHa Luteinizing hormone-releasing hormone agonist